Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-11-08
2005-11-08
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S009200, C424S199100, C424S200100, C435S006120
Reexamination Certificate
active
06962790
ABSTRACT:
The present invention relates to an in vitro method for determining the ability of a vaccine composition which comprises one or more antigens or a nucleic acid molecule which encodes one or more antigens to stimulate a T cell response. In one embodiment, the method comprises the steps of: (1) contacting antigen presenting cells in culture with a vaccine composition selected from among the group of vaccine compositions, thereby, if one or more of the antigens or nucleic acid molecules can be taken up and processed by the antigen presenting cells, producing one or more processed antigens; (2) contacting the antigen presenting cells with T cells under conditions sufficient for the T cells to respond to one or more of the processed antigens; (3) determining whether the T cells respond to one or more of the processed antigens; whereby if the T cells respond to one or more of the processed antigens, then the vaccine composition stimulates a T cell response; and (4) repeating steps (1), (2) and (3) with each vaccine composition in the group, thereby identifying vaccine compositions which stimulate a T cell response; and, if one or more of the vaccine compositions stimulates a T cell response, (5) selecting at least one vaccine composition which stimulates a T cell response for assessment in one or more animals and/or human subjects.
REFERENCES:
patent: 5200320 (1993-04-01), Sette et al.
patent: 5674502 (1997-10-01), Ennis
patent: 5750356 (1998-05-01), Spack et al.
patent: 5763284 (1998-06-01), Tal et al.
patent: 5766601 (1998-06-01), Ennis
patent: 5962318 (1999-10-01), Rooney et al.
patent: 6627407 (2003-09-01), Ennis
patent: WO 94/22917 (1994-10-01), None
Sette et al, Nature, 328, 395-399, 1987.
Baier et al, Journal of Virology, 69, 2357-2365, 1995.
Gotch et al, Journal of Experimental Medicine, 165, 408-416, 1987.
McMichael et al, Journal of General Virology, 67, 719-726, 1986.
Wisdom,Peptide Antigens, A Practical Approach, Oxford University Press, 1994, Chapters 1, 4 and 7.
Zegers et al,Immunological Recognition of Peptides in Medicine and Biology, CRC Press, 1995. Chapter 8.
Reitan, L.J. and Secombes, C.J., “In Vitro Methods for Vaccine Evaluation,”Dev. Biol. Stand. 90:293-301 (1997).
Lein, A.D. and von Reyn, C.F., “In Vitro Cellular and Cytokine Responses to Mycobacterial Antigens: Application to Diagnosis of Tuberculosis Infection and Assessment of Response to Mycobacterial Vaccines,”The American Journal of the Medical Sciences, 313(6):364-371 (1997).
Smith, G.L., et al., “Synthesis and Cellular Location of the Ten Influenza Polypeptides Individually Expressed by Recombinant Vaccinia Viruses,”Virology 160:336-345 (1987).
Böyum, A., “Isolation of Mononuclear Cells and Granulocytes from Human Blood,” Scand. J. Clin. Lab. Invest. 21 (Suppl. 97):77-89 (1968).
Kurane, I., et al., “Dengue Virus-Specific Human T Cell Clones, Serotype Crossreactive Proliferation, Interferon γ Production, and Cytotoxic Activity,”J. Exp. Med. 170:763-775 (1989).
Fathman, C.G., et al., “Long-Term Culture of Immunocompetent Cells,” in Paul, ed.,Fundamental Immunology, 2nd Ed.,New York: Raven Press, Chapter 30:803-815 (1989).
Green, S., et al., “Dengue Virus-Specific Human CD4+T-Lymphocyte Responses in a Recipient of an Experimental Live-Attenuated Dengue Virus Type 1 Vaccine: Bulk Culture Proliferation, Clonal Analysis, and Precursor Frequency Determination,”J. Virol. 67(10):5962-5967 (1993).
Littaua, R.A., et al., “An HLA-C Restricted CD8+Cytotoxic T-Lymphocyte Clone Recognizes a Highly Conserved Epitope on Human Immunodeficiency Virus Type 1 gag,”J. Virol. 65(8):4051-4056 (1991).
Kuwano, K., et al., “Cross-Reactive Protection Against Influenza A Virus Infections by an NS1-Specific CTL Clone,”Virology 178:174-179 (1990).
Kuwano, K., et al., “HA2 Subunit of Influenza A H1 and H2 Subtype Viruses Induces a Protective Cross-Reactive Cytotoxic T Lymphocyte Response,”J. of Immunology 140(4):1264-1268 (1988).
Jameson, J., et al., “Human Cytotoxic T-Lymphocyte Repertoire to Influenza A Viruses,”J. Virol. 72(11) :8682-8689 (1998).
Claassen, I. and Osterhaus, A., “The iscom structure as an immune-enhancing moiety: experience with viral systems,”Res. Immunol. 143(5):531-541 (1992).
Hamilton Brook Smith & Reynolds P.C.
Saunders David
University of Massachusetts Medical Center
LandOfFree
Predictive assay for immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Predictive assay for immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Predictive assay for immune response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3509534